ER negative

P2, N=50, Recruiting, Wake Forest University Health Sciences | Trial completion date: Apr 2026 --> Aug 2026 | Trial primary completion date: Apr 2026 --> Aug 2026

P2, N=16, Recruiting, Wake Forest University Health Sciences | Trial completion date: Jan 2027 --> Jul 2027

P1/2, N=75, Active, not recruiting, Massachusetts General Hospital | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2025 --> Jun 2026

Biomarker-stratified analyses showed worse OS for ER-negative tumors and nominally better iDFS for Ki-67-negative tumors. Tumor burden and proliferative activity can guide risk-stratified chest imaging surveillance and early pathology correlation to distinguish metastasis from new primaries during BC follow-up.

Key diagnostic clues and common pitfalls are discussed, underscoring a practical workflow in which ER negativity serves as a diagnostic signal rather than a terminal category. Improved recognition and subclassification of ER-negative endometrial carcinomas are essential for accurate diagnosis, prognostic stratification, and optimized clinical management.

ARID1A mutation was associated with worse PFS for patients with NSMP. ARID1A protein expression was significantly associated with ARID1A mutation. ARID1A mutation, with ER/PR expression and PIK3CA mutation status, could serve as the potential biomarkers to subclassify NSMP subtype and provide more precise therapeutic target.

P3, N=55, Terminated, Biocon Biologics UK Ltd | N=382 --> 55 | Trial completion date: Nov 2026 --> Dec 2025 | Recruiting --> Terminated; US FDA is streamlining the Biosimilar development. Thus, Biocon decided to terminate the study.

This study identified distinct expression patterns of FABPs across breast cancer subtypes and highlighted their potential roles in immune modulation. These findings offer new insights into the diverse functions of FABPs in breast cancer and their implications for prognosis.

These predictors of pathologically negative ALN and RFS after NAC are useful for planning appropriate surgical and adjuvant treatment for BC patients.

Lifestyle patterns linked to elevated 2-OH of estrogen were associated with lower risk of postmenopausal breast and endometrial cancers. Our study provides evidence for lifestyle modifications for cancer prevention.

The study by Moyer and colleagues demonstrated that RXR agonists, particularly IRX4204, delay tumor onset in BRCA1-deficient and triple-negative mouse models, suggesting a potential preventive role through immunomodulation...A rational next step may be to carefully design window-of-opportunity trials in BRCA1 carriers undergoing risk-reducing bilateral mastectomy to assess biomarker modulation and tolerability. See related article by Moyer et al., p. 161.

ER negativity and HER-2 positivity emerge as independent predictive factors for pCR, with ER and HER-2 exhibiting the strongest discriminative ability (AUC > 0.8). Clinicians should integrate patients' baseline clinical data, ultrasound features, and molecular markers to screen optimal NAC candidates and develop individualized strategies, thereby maximizing therapeutic benefits.